Innorules Co.,Ltd (KOSDAQ:296640)

Verve Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	24,643	23,707	15,511	16,231	16,405	11,405
Other Revenue	-	-	-	-0	-0	-
Revenue	24,643	23,707	15,511	16,231	16,405	11,405
Revenue Growth (YoY)	49.21%	52.84%	-4.44%	-1.06%	43.84%	-18.87%
Cost of Revenue	11,179	10,902	8,338	6,642	6,078	4,569
Gross Profit	13,464	12,805	7,172	9,590	10,327	6,837
Selling, General & Admin	8,094	7,766	6,186	6,107	5,519	4,177
Research & Development	2,278	2,090	1,859	1,866	1,427	1,091
Other Operating Expenses	102.16	96.19	73.36	77.96	46.31	49.68
Operating Expenses	11,024	10,477	8,413	8,302	7,217	5,527
Operating Income	2,441	2,328	-1,241	1,288	3,109	1,310
Interest Expense	-105.15	-105.15	-14.32	-21.12	-69	-191.07
Interest & Investment Income	923.51	923.51	885.35	359.92	64.05	45.03
Currency Exchange Gain (Loss)	-2.2	-2.2	-14.12	-27.29	-7.06	-12.88
Other Non Operating Income (Expenses)	96.43	59.91	-32.08	-7.57	51.01	250.09
EBT Excluding Unusual Items	3,353	3,204	-415.79	1,592	3,148	1,401
Gain (Loss) on Sale of Investments	-10.93	-10.93	11.04	-	-	8.48
Gain (Loss) on Sale of Assets	-7.67	-7.67	-6.14	-1.31	-0.02	0.26
Other Unusual Items	-	-	-	-	-	163.95
Pretax Income	3,335	3,185	-410.89	1,591	3,148	1,573
Income Tax Expense	140.87	113.48	-445.67	-557.51	314.73	-567.21
Earnings From Continuing Operations	3,194	3,072	34.78	2,149	2,833	2,141
Earnings From Discontinued Operations	-	-	-	-	-	-329.88
Net Income	3,194	3,072	34.78	2,149	2,833	1,811
Net Income to Common	3,194	3,072	34.78	2,149	2,833	1,811
Net Income Growth	256.76%	8731.34%	-98.38%	-24.17%	56.48%	97.41%
Shares Outstanding (Basic)	5	5	5	4	3	3
Shares Outstanding (Diluted)	5	5	5	4	3	3
Shares Change (YoY)	2.98%	-1.51%	18.95%	23.95%	13.20%	7.97%
EPS (Basic)	631.79	607.08	6.79	500.40	813.16	588.29
EPS (Diluted)	621.08	607.00	6.79	497.00	813.00	587.83
EPS Growth	254.45%	8845.35%	-98.63%	-38.87%	38.31%	82.69%
Free Cash Flow	2,355	3,942	334.45	3,200	1,996	1,051
Free Cash Flow Per Share	447.17	779.11	65.10	740.92	572.79	341.40
Dividend Per Share	250.000	250.000	-	-	-	-
Gross Margin	54.64%	54.01%	46.24%	59.08%	62.95%	59.94%
Operating Margin	9.90%	9.82%	-8.00%	7.94%	18.95%	11.48%
Profit Margin	12.96%	12.96%	0.22%	13.24%	17.27%	15.88%
Free Cash Flow Margin	9.56%	16.63%	2.16%	19.72%	12.17%	9.21%
EBITDA	2,939	2,800	-898.82	1,551	3,343	1,951
EBITDA Margin	11.93%	11.81%	-5.79%	9.55%	20.38%	17.11%
D&A For EBITDA	498.21	471.98	341.79	262.11	233.94	641.76
EBIT	2,441	2,328	-1,241	1,288	3,109	1,310
EBIT Margin	9.90%	9.82%	-8.00%	7.94%	18.95%	11.48%
Effective Tax Rate	4.22%	3.56%	-	-	10.00%	-
Advertising Expenses	-	33.32	87.1	24.41	2	14.51

Source: S&P Global Market Intelligence. Standard template. Financial Sources.